- Home
- ALCYU vs IDYA Comparison
ALCYU vs IDYA Comparison
Compare ALCYU & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALCYU
- IDYA
- Stock Information
- Founded
- ALCYU N/A
- IDYA 2015
- Country
- ALCYU
- IDYA United States
- Employees
- ALCYU 3
- IDYA N/A
- Industry
- ALCYU
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- ALCYU
- IDYA Health Care
- Exchange
- ALCYU NYSE
- IDYA Nasdaq
- Market Cap
- ALCYU N/A
- IDYA 2.6B
- IPO Year
- ALCYU N/A
- IDYA 2019
- Fundamental
- Price
- ALCYU $10.88
- IDYA $30.47
- Analyst Decision
- ALCYU
- IDYA Strong Buy
- Analyst Count
- ALCYU 0
- IDYA 10
- Target Price
- ALCYU N/A
- IDYA $56.00
- AVG Volume (30 Days)
- ALCYU N/A
- IDYA 997.5K
- Earning Date
- ALCYU N/A
- IDYA 11-05-2024
- Dividend Yield
- ALCYU N/A
- IDYA N/A
- EPS Growth
- ALCYU N/A
- IDYA N/A
- EPS
- ALCYU N/A
- IDYA N/A
- Revenue
- ALCYU N/A
- IDYA $11,961,000.00
- Revenue This Year
- ALCYU N/A
- IDYA N/A
- Revenue Next Year
- ALCYU N/A
- IDYA $94.96
- P/E Ratio
- ALCYU N/A
- IDYA N/A
- Revenue Growth
- ALCYU N/A
- IDYA N/A
- 52 Week Low
- ALCYU N/A
- IDYA $23.41
- 52 Week High
- ALCYU N/A
- IDYA $47.74
- Technical
- Relative Strength Index (RSI)
- ALCYU 39.72
- IDYA 41.00
- Support Level
- ALCYU $10.81
- IDYA $28.69
- Resistance Level
- ALCYU $10.96
- IDYA $31.54
- Average True Range (ATR)
- ALCYU 0.00
- IDYA 1.42
- MACD
- ALCYU 0.00
- IDYA 0.17
- Stochastic Oscillator
- ALCYU 0.00
- IDYA 56.51
About ALCYU ALCHEMY INVTS ACQUISITION CORP 1 UNIT 1 CL A COM & 1/2 WT
Alchemy Investments Acquisition Corp 1 is a blank check company.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.